Medivation Inc (MDVN) 57.93 $MDVN
Medivation Appoints Patrick Machado to Board of Directors
Marketwire - Thu Apr 17, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that Patrick Machado has been appointed to the Company's board of directors. Mr. Machado recently retired from his role as chief financial and business officer, and will formally retire from Medivation on April 18, 2014.
Johnson and Johnson Earnings Surprises With Blockbuster Potential
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Apr 16, 1:52PM CDT
Editor's Note: In the video below, Olysio's sales for the quarter are identified as $365 million. Olysio's actual sales were $354 million. The Fool regrets the error. Johnson and Johnson reported quarterly earnings on Tuesday, and one...
19.8% Return Seen to Date on SmarTrend Medivation Call (MDVN)
Comtex SmarTrend(R) - Wed Apr 16, 9:10AM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 2 months, Medivation has returned 19.84% as of today's recent price of $58.86.
Medivation (MDVN) Marked As A Dead Cat Bounce Stock
at The Street - Mon Apr 14, 8:48AM CDT
Trade-Ideas LLC identified Medivation (MDVN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys
PR Newswire - Mon Apr 14, 7:16AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN, MDVN, MSTX and ATHX can be downloaded upon signing up at:
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Shares of MDVN Down 17.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 08, 4:51PM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 1 month, Medivation has returned 17.77% as of today's recent price of $60.38.
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Bayer Initiates Xofigo Combination Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:30PM CDT
Bayer initiated a phase III study on Xofigo for the treatment of patients suffering from bone predominant metastatic CRPC.
Earnings Releases, Stock Price Movements, Company Milestone, Senior-level Appointments - Analyst Notes on Avalonbay, Medivation, Hertz, Marriott, and Accenture
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Avalonbay Communities Inc. (NYSE: AVB), Medivation, Inc. (NASDAQ: MDVN), Hertz Global Holdings, Inc. (NYSE: HTZ), Marriott International, Inc. (NASDAQ: MAR), and Accenture plc (NYSE: ACN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Astellas Announces European Regulatory Submission For XTANDI® (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
PR Newswire - Thu Apr 03, 6:00AM CDT
Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. XTANDI is currently approved in Europe for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel chemotherapy.
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone
Medivation Shares Down 9.7% Since SmarTrend's Sell Call (MDVN)
Comtex SmarTrend(R) - Tue Apr 01, 11:10AM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 1 month, Medivation has returned 9.66% as of today's recent price of $66.33.
Medivation appoints Rick Bierly as CFO
M2 - Tue Apr 01, 5:42AM CDT
US-based biopharmaceutical company Medivation (NASDAQ:MDVN) disclosed on Monday the addition of Rick Bierly as its chief financial officer.
Exelixis Continues On
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:42PM CDT
Shares of Exelixis got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of...
Medivation Names Rick Bierly Chief Financial Officer
Marketwire - Mon Mar 31, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced the appointment of Rick Bierly as chief financial officer, effective March 31, 2014. Rick will serve as Medivation's principal financial and accounting officer and will report to David Hung, M.D., president and chief executive officer.
Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 28, 7:30PM CDT
Favorable economic news helped send the stock market higher despite the usual pre-weekend jitters on Wall Street, as larger gains earlier in the day gave way to traders once again choosing not to hold onto positions in light of geopolitical...
After Yesterday's Decline of 3.31%, Medivation Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 28, 4:37PM CDT
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $60.61 to a high of $64.50. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $61.90 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Exelixis Inc's Comet Fails To Dazzle
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Astronomers have grown very cautious over the years about predicting which comets will brighten the night skies, as all too many have failed to live up to expectation. Small biotech Exelixis ' own comet, the COMET-1 study of cabozantinib in...
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Medivation Appoints Patrick Machado to Board of Directors
Marketwire - Thu Apr 17, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that Patrick Machado has been appointed to the Company's board of directors. Mr. Machado recently retired from his role as chief financial and business officer, and will formally retire from Medivation on April 18, 2014.
Johnson and Johnson Earnings Surprises With Blockbuster Potential
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Apr 16, 1:52PM CDT
Editor's Note: In the video below, Olysio's sales for the quarter are identified as $365 million. Olysio's actual sales were $354 million. The Fool regrets the error. Johnson and Johnson reported quarterly earnings on Tuesday, and one...
19.8% Return Seen to Date on SmarTrend Medivation Call (MDVN)
Comtex SmarTrend(R) - Wed Apr 16, 9:10AM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 2 months, Medivation has returned 19.84% as of today's recent price of $58.86.
Medivation (MDVN) Marked As A Dead Cat Bounce Stock
at The Street - Mon Apr 14, 8:48AM CDT
Trade-Ideas LLC identified Medivation (MDVN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys
PR Newswire - Mon Apr 14, 7:16AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN, MDVN, MSTX and ATHX can be downloaded upon signing up at:
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Shares of MDVN Down 17.8% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 08, 4:51PM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 1 month, Medivation has returned 17.77% as of today's recent price of $60.38.
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Bayer Initiates Xofigo Combination Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:30PM CDT
Bayer initiated a phase III study on Xofigo for the treatment of patients suffering from bone predominant metastatic CRPC.
Earnings Releases, Stock Price Movements, Company Milestone, Senior-level Appointments - Analyst Notes on Avalonbay, Medivation, Hertz, Marriott, and Accenture
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Avalonbay Communities Inc. (NYSE: AVB), Medivation, Inc. (NASDAQ: MDVN), Hertz Global Holdings, Inc. (NYSE: HTZ), Marriott International, Inc. (NASDAQ: MAR), and Accenture plc (NYSE: ACN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Astellas Announces European Regulatory Submission For XTANDI® (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
PR Newswire - Thu Apr 03, 6:00AM CDT
Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. XTANDI is currently approved in Europe for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel chemotherapy.
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone
Medivation Shares Down 9.7% Since SmarTrend's Sell Call (MDVN)
Comtex SmarTrend(R) - Tue Apr 01, 11:10AM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 1 month, Medivation has returned 9.66% as of today's recent price of $66.33.
Medivation appoints Rick Bierly as CFO
M2 - Tue Apr 01, 5:42AM CDT
US-based biopharmaceutical company Medivation (NASDAQ:MDVN) disclosed on Monday the addition of Rick Bierly as its chief financial officer.
Exelixis Continues On
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:42PM CDT
Shares of Exelixis got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of...
Medivation Names Rick Bierly Chief Financial Officer
Marketwire - Mon Mar 31, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced the appointment of Rick Bierly as chief financial officer, effective March 31, 2014. Rick will serve as Medivation's principal financial and accounting officer and will report to David Hung, M.D., president and chief executive officer.
Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 28, 7:30PM CDT
Favorable economic news helped send the stock market higher despite the usual pre-weekend jitters on Wall Street, as larger gains earlier in the day gave way to traders once again choosing not to hold onto positions in light of geopolitical...
After Yesterday's Decline of 3.31%, Medivation Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 28, 4:37PM CDT
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $60.61 to a high of $64.50. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $61.90 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Exelixis Inc's Comet Fails To Dazzle
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Astronomers have grown very cautious over the years about predicting which comets will brighten the night skies, as all too many have failed to live up to expectation. Small biotech Exelixis ' own comet, the COMET-1 study of cabozantinib in...
Healthcare Companies Make Presentations, Submissions, Investigation Extensions, and Expansions - Analyst Notes on CR Bard, Medivation, Align Technology, Covance, and PAREXEL
PR Newswire - Fri Mar 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding CR Bard Inc. (NYSE: BCR), Medivation, Inc. (NYSE: MDVN), Align Technology Inc. (NASDAQ: ALGN), Covance Inc. (NYSE: CVD), and PAREXEL International Corporation (NASDAQ: PRXL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
